Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

Caribou Biosciences, Inc. — Intellia Therapeutics, Inc. insider: 2 transactions · InsiderLens

Home / Insiders / Caribou Biosciences, Inc.

Caribou Biosciences, Inc.

10% owner at Intellia Therapeutics, Inc. · on record since May 11, 2016

Insider trading activity of Caribou Biosciences, Inc.

Transactions on record: 2; since Sep 13, 2017

Open-market buys: 0

Open-market sells: 2; $14.7M

Companies traded: 1; last filing Jan 30, 2018

Figures computed from official regulatory filings — methodology.

Companies where Caribou Biosciences, Inc. has traded

Intellia Therapeutics, Inc.2 tx · $14.7M · Jan 30, 2018

Track record of Caribou Biosciences, Inc.

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Caribou Biosciences, Inc.

Co-insiders of Caribou Biosciences, Inc.

Atlas Venture Associates IX, LLCIntellia Therapeutics, Inc.
Atlas Venture Associates IX, L.P.Intellia Therapeutics, Inc.
Atlas Venture Fund IX, L.P.Intellia Therapeutics, Inc.
Baker Bros. Advisors (GP) LLCIntellia Therapeutics, Inc.
BAKER BROS. ADVISORS LPIntellia Therapeutics, Inc.
BAKER FELIXIntellia Therapeutics, Inc.
BAKER JULIANIntellia Therapeutics, Inc.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

Barnes Thomas M.Intellia Therapeutics, Inc.

BASTA JAMESIntellia Therapeutics, Inc.

Bell GraemeIntellia Therapeutics, Inc.

Bermingham NessanIntellia Therapeutics, Inc.

Bhanji MunaIntellia Therapeutics, Inc.

Caribou Therapeutics Holdco, LLCIntellia Therapeutics, Inc.

CHASE WILLIAM JIntellia Therapeutics, Inc.

Clark ElianaIntellia Therapeutics, Inc.

Cohen Fred EIntellia Therapeutics, Inc.

Crowley John FIntellia Therapeutics, Inc.

DORSA CAROLINEIntellia Therapeutics, Inc.

Dube Michael PIntellia Therapeutics, Inc.

Dulac Edward J IIIIntellia Therapeutics, Inc.

Foresite Capital Fund III, L.P.Intellia Therapeutics, Inc.

Foresite Capital Management III, LLCIntellia Therapeutics, Inc.

FORMELA JEAN FRANCOISIntellia Therapeutics, Inc.

Fullerton Management Pte LtdIntellia Therapeutics, Inc.

Goddard GlennIntellia Therapeutics, Inc.

Goff BrianIntellia Therapeutics, Inc.

GOODMAN JESSEIntellia Therapeutics, Inc.

GORDON CARL LIntellia Therapeutics, Inc.

Haurwitz Rachel E.Intellia Therapeutics, Inc.

HAYES JOHN T.Intellia Therapeutics, Inc.

Heifner NicoleIntellia Therapeutics, Inc.

Hicks DerekIntellia Therapeutics, Inc.

ISALY SAMUEL DIntellia Therapeutics, Inc.

KARSEN PERRY AIntellia Therapeutics, Inc.

Keresty GeorgiaIntellia Therapeutics, Inc.

Lebwohl DavidIntellia Therapeutics, Inc.

LEONARD JOHN MIntellia Therapeutics, Inc.

Morrissey David VIntellia Therapeutics, Inc.

NOVARTIS AGIntellia Therapeutics, Inc.

Novartis Institutes for BioMedical Research, Inc.Intellia Therapeutics, Inc.

ORBIMED ADVISORS LLCIntellia Therapeutics, Inc.

OrbiMed Capital GP V LLCIntellia Therapeutics, Inc.

OrbiMed Global Healthcare GP LLCIntellia Therapeutics, Inc.

Rivera Jose EIntellia Therapeutics, Inc.

SCHIERMEIER ANDREWIntellia Therapeutics, Inc.

Schultes Birgit CIntellia Therapeutics, Inc.

Sepp-Lorenzino LauraIntellia Therapeutics, Inc.

Slaoui MoncefIntellia Therapeutics, Inc.

Srivastava SapnaIntellia Therapeutics, Inc.

Tananbaum James B.Intellia Therapeutics, Inc.

Company	Filed	Type	Qty	Price	Value · USD	Src
Intellia Therapeutics, Inc.	Jan 30, 2018	Sell	-550,645	26.78 USD	$14.7M	SEC
Intellia Therapeutics, Inc.	Sep 13, 2017	Sell	-1,048,846	—	—	SEC